Clinical Trials Logo

Clinical Trial Summary

This study will assess the safety and tolerability of RotaTeq™ (V260) in the healthy Chinese populations. Approximately 144 participants will be enrolled and equally stratified into three age cohorts, Cohort I ages 19-47 years, Cohort II ages 2-6 years, and Cohort III ages 6-12 weeks. Randomization ratio is 1:1 in each cohort. The study will be conducted sequentially, participants in Cohort I then Cohort II receiving 1 dose of, and then participants in Cohort III receiving 3 doses of RotaTeq™/placebo. The primary investigator and the Ethics Review Committee will review blinded safety data and make decision based on their best clinical judgment to move study forward between cohorts. Duration for the entire study will be approximately 6-9 months.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00953056
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 1
Start date September 2009
Completion date March 2010

See also
  Status Clinical Trial Phase
Completed NCT01575197 - Evaluation of the Human Rotavirus Vaccine at Varying Schedules and Doses in Rural Ghana Phase 4
Completed NCT01202201 - A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and Nosocomial RV GE in Japan N/A
Completed NCT00737503 - Introduction of an Oral Live Human Rotavirus (Rotarix) Vaccine in Matlab Phase 4
Completed NCT04185545 - Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates Phase 3
Completed NCT03474055 - Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India Phase 2/Phase 3
Completed NCT01236066 - Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia N/A
Completed NCT00489567 - Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in Sweden N/A
Completed NCT02584816 - Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization Phase 3
Completed NCT02062385 - Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024) Phase 3
Completed NCT02133690 - A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants Phase 3
Completed NCT01177657 - Study to Evaluate the Effectiveness of Rotarix™ Against Severe Gastroenteritis Among Hospitalized Children in Brazil N/A
Completed NCT00740935 - Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France. Phase 4
Completed NCT01265355 - Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement Phase 2/Phase 3
Completed NCT00169455 - Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants Phase 3
Completed NCT04819412 - To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus Phase 3
Completed NCT02728869 - Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants Phase 1/Phase 2
Recruiting NCT05958771 - The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E Phase 3
Recruiting NCT01061658 - Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine Phase 1/Phase 2
Completed NCT01026779 - Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island
Completed NCT01508533 - Epidemiology of Rotavirus Infection in North India Community N/A